Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9Y4F4

UPID:
TGRM1_HUMAN

ALTERNATIVE NAMES:
Crescerin-1; Protein FAM179B

ALTERNATIVE UPACC:
Q9Y4F4; Q68D66; Q6PG27

BACKGROUND:
The TOG array regulator of axonemal microtubules protein 1, known alternatively as Crescerin-1 or Protein FAM179B, is essential for ciliogenesis. It facilitates the acetylation and polyglutamylation of ciliary microtubules, regulating cilium length. Through its interaction with microtubules and enhancement of microtubule polymerization, particularly via HEAT repeat domains in TOG regions 2 and 4, it plays a critical role in cellular architecture and dynamics.

THERAPEUTIC SIGNIFICANCE:
As it is implicated in Joubert syndrome 37, characterized by a spectrum of neurological and physical manifestations, the study of TOG array regulator of axonemal microtubules protein 1 holds potential for therapeutic innovation. Exploring its function in ciliogenesis and microtubule regulation could pave the way for targeted treatments for this autosomal recessive condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.